Minerva Neurosciences, Inc.
NERV Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.30
KIRA · Stoqly’s AI analyst, in plain words
- Minerva Neurosciences, Inc. lost $293M in fiscal 2025.
Market cap
$182M
P/E
—
Revenue
—
Net income
−$293M
Free cash flow
—
Operating margin
—
Minerva Neurosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$293M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Minerva Neurosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- Minerva Neurosciences, Inc.
- CIK
- 0001598646
Minerva Neurosciences, Inc. · NERV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Revenue growth | −100.0% | — | — | — | — |
| Net income | −$49.9M | −$32.1M | −$30.0M | $1.4M | −$293M |
| Diluted EPS | −$9.35 | −$6.01 | −$4.61 | $0.19 | −$34.67 |
| Cash | |||||
| Cash from operations | −$24.6M | −$24.6M | −$14.8M | −$19.6M | −$13.5M |
| Capital expenditure | — | $0.0M | — | — | — |
| Free cash flow | — | −$24.7M | — | — | — |
| Share count change | −86.9% | 0.0% | 21.8% | 16.4% | 11.7% |
| Debt and strength | |||||
| Cash and short-term investments | $60.8M | $36.1M | $40.9M | $21.4M | $82.3M |
| Shareholders' equity | $8.0M | −$20.0M | −$28.5M | −$25.7M | −$141M |
| Current ratio | 22.1x | 29.2x | 12.6x | 7.9x | 36.3x |
| Returns and quality | |||||
| Return on equity | −164.6% | — | — | — | — |
| Piotroski F-score | 3 | 4 | 2 | 2 | — |
| Altman Z'' | −12.9 | −20.4 | −21.4 | −35.7 | −19.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Minerva Neurosciences, Inc. · NERV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.30 a share, the company is worth $182M.
Source: SEC EDGAR XBRL filings (CIK 0001598646). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.